> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Preemption Cited in Gadolinium Case
- URL: https://www.fdaweb.com/preemption-cited-in-gadolinium-case/
- Published: 2020-03-18T12:00:00.000Z
- Updated: 2026-09-14T16:07:49.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146358

A Louisiana federal judge has ruled that design defect and failure-to-warn claims brought against a gadolinium contrast agent manufacturer are preempted by federal law. Attorney **Steven Boranian** (Reed Smith) [says](https://www.druganddevicelawblog.com/2020/03/gadolinium-plaintiff-runs-into-preemption-wall-in-louisiana.html?ref=fdaweb.com) the decision is a good example of how preemption should work. Writing in the *Drug and Device Law* blog. Boranian describes how the court applied federal exemption to each of the claims. “The facts lined up to meet all the applicable legal standards,” he concludes. “A perfect storm maybe. Or maybe just a fair result. We like the latter.”